<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04957147</url>
  </required_header>
  <id_info>
    <org_study_id>19IC5198</org_study_id>
    <nct_id>NCT04957147</nct_id>
  </id_info>
  <brief_title>Reverse Remodelling and Remission Markers in the Serial Evaluation of Recent-onset Dilated Cardiomyopathy</brief_title>
  <acronym>REMIT-DCM</acronym>
  <official_title>The REMIT-DCM Study: Reverse Remodelling and Remission Markers in the Serial Evaluation of Recent-onset Dilated Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Royal Brompton &amp; Harefield NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Approximately 30-40% of patients with non-ischaemic dilated cardiomyopathy (DCM) undergo&#xD;
      significant left ventricular reverse remodelling in response to guideline-directed therapies.&#xD;
      This is characterised by improvement in systolic dysfunction and regression of left&#xD;
      ventricular dilatation. In some patients, extensive left ventricular reverse remodelling is&#xD;
      accompanied by resolution of symptoms and normalisation of cardiac biomarkers, resulting in a&#xD;
      state of clinical remission.&#xD;
&#xD;
      The mechanistic drivers behind left ventricular reverse remodelling and clinical remission&#xD;
      are poorly understood. Current techniques to predict ventricular remodelling trajectory and&#xD;
      clinical remission in patients with recent-onset DCM are limited.&#xD;
&#xD;
      The purpose of this study is to characterise predictors and markers of left ventricular&#xD;
      reverse remodelling and clinical remission in patients with recent-onset DCM using molecular&#xD;
      markers, genetics and advanced CMR imaging.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The REMIT-DCM study is a single-centre pilot observational cohort study. 70 patients with&#xD;
      recent-onset DCM (Group A) and up to 40 healthy volunteers (Group B) will be recruited.&#xD;
      Patients with DCM will be recruited over a 2-year period and will be followed up for 12&#xD;
      months. Subjects in Group A may be offered an optional further study visit at 24-48 months&#xD;
      after enrolment in order to assess whether cardiac remodelling and clinical remission are&#xD;
      sustained over the intermediate-term.&#xD;
&#xD;
      Patients with DCM (Group A) will attend 3 study visits at The Royal Brompton Hospital&#xD;
      (baseline, 2-3 months and 12 months). Each study visit will involve a clinical consultation,&#xD;
      blood sample collection (including routine clinical blood tests and sample storage for&#xD;
      exploratory biomarkers), urine sample collection, 12-lead ECG, health questionnaire&#xD;
      completion and a cardiovascular magnetic resonance scan (CMR). If patients are unable to have&#xD;
      a CMR, 3D transthoracic echocardiography will be performed.&#xD;
&#xD;
      Healthy volunteers will attend a single study visit at The Royal Brompton Hospital. This will&#xD;
      involve a clinical consultation, blood sample collection (including routine clinical blood&#xD;
      tests and sample storage for exploratory biomarkers), urine sample collection, 12-lead ECG,&#xD;
      health questionnaire completion and a CMR.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">September 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 28, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical remission</measure>
    <time_frame>12-months</time_frame>
    <description>If all 3 of the following criteria are met at 12-month assessment:&#xD;
i. Increase in left ventricular ejection fraction (LVEF) by ≥ 10% to a value ≥ 50% and decrease in indexed left ventricular end diastolic volume (LVEDV) to within normal range according to age-/sex-corrected normograms.&#xD;
ii. NYHA class I.&#xD;
iii. NT-Pro BNP &lt;250 ng/L.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left ventricular reverse remodelling</measure>
    <time_frame>12-months</time_frame>
    <description>Evaluated by changes in indexed left ventricular end systolic volume (LVESV), indexed LVEDV and LVEF between baseline and 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular reverse remodelling</measure>
    <time_frame>12-months</time_frame>
    <description>Evaluated using a pre-specified threshold: patients with DCM will be divided into 2 groups at the 12-month timepoint:&#xD;
i. Left ventricular reverse remodelling: an increase in LVEF by ≥ 10% to a value ≥ 40%; and a decrease in indexed LVEDV by ≥ 10%.&#xD;
ii. No left ventricular reverse remodelling: no increase in LVEF by ≥ 10% to a value ≥ 40% and/or no decrease in indexed LVEDV by ≥ 10%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiovascular events</measure>
    <time_frame>12-months</time_frame>
    <description>Composite of cardiovascular death, major heart failure or major arrhythmic events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in health status using Kansas City Cardiomyopathy questionnaire</measure>
    <time_frame>12-months</time_frame>
    <description>Change in Kansas City Cardiomyopathy questionnaire scores from baseline to 12-months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in health status using SF-12 questionnaire</measure>
    <time_frame>12-months</time_frame>
    <description>Change in SF-12 questionnaire scores from baseline to 12-months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in health status using EQ-5D questionnaire</measure>
    <time_frame>12-months</time_frame>
    <description>Change in EQ-5D questionnaire scores from baseline to 12-months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained clinical remission at 24-48 months after enrolment</measure>
    <time_frame>48 months</time_frame>
    <description>For those in clinical remission at 12-month timepoint, the proportion that have sustained clinical remission at 24-48 months after enrolment.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Dilated Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Group A: patients with dilated cardiomyopathy</arm_group_label>
    <description>Patients with recent-onset dilated cardiomyopathy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: healthy volunteers</arm_group_label>
    <description>Healthy volunteers with no known heart disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>12 months of guideline-directed heart failure therapy</intervention_name>
    <description>Standard guideline-directed heart failure drug +/- device therapy</description>
    <arm_group_label>Group A: patients with dilated cardiomyopathy</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and urine samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Group A: There are 3 routes via which patients with DCM may be recruited:&#xD;
&#xD;
          1. Patients from the Royal Brompton &amp; Harefield NHS Trust clinical service (inpatients,&#xD;
             patients from clinics and patients referred for a CMR).&#xD;
&#xD;
          2. Patients with DCM may also be recruited from collaborating district general hospitals,&#xD;
             defined as Patient Identification Centres (PICs). Clinicians at these sites have&#xD;
             agreed to identify suitable patients encountered within their routine practice.&#xD;
&#xD;
          3. Patients will be able to self-refer via The Heart Hive for consideration by the study&#xD;
             team. The Heart Hive (https://www.thehearthive.org/) is an online platform that offers&#xD;
             patients with cardiomyopathy and healthy volunteers the opportunity to connect with&#xD;
             researchers regarding participation in research studies.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        For DCM cohort (Group A):&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥16.&#xD;
&#xD;
          -  Able to give informed consent.&#xD;
&#xD;
          -  Confirmed DCM with symptom-onset within the last 6 months and LVEF ≤ 45%. The&#xD;
             diagnosis of DCM will be confirmed using the European Society of Cardiology&#xD;
             definition, based on reduced LVEF and elevated LV end-diastolic volume indexed to body&#xD;
             surface area, compared to published age- and sex-specific reference values&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant coronary artery heart disease, defined as a stenosis of &gt;50% of an&#xD;
             epicardial coronary artery affecting the proximal or mid-portion of the vessel on&#xD;
             invasive angiography or computed tomography coronary angiography (CTCA), previous&#xD;
             percutaneous coronary intervention, CMR late gadolinium enhancement pattern suggestive&#xD;
             of previous myocardial infarction of ≥ 2 segments of ≥ 50% transmural infarction of&#xD;
             the LV wall.&#xD;
&#xD;
          -  High suspicion of concomitant hypertrophic cardiomyopathy, amyloidosis, Fabry disease,&#xD;
             sarcoidosis, active myocarditis, Chagas disease or hemochromatosis.&#xD;
&#xD;
          -  History of primary valvular heart disease or congenital heart disease.&#xD;
&#xD;
          -  Severe, untreated or untreatable hypertension (systolic blood pressures routinely &gt;180&#xD;
             mm Hg and/or diastolic blood pressures &gt;120 mm Hg)&#xD;
&#xD;
          -  Pregnancy and/or breastfeeding.&#xD;
&#xD;
          -  Severe renal disease (GFR &lt;15 mls/min).&#xD;
&#xD;
        For healthy volunteer cohort (Group B):&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥16.&#xD;
&#xD;
          -  Able to give informed consent.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Participants with any clinically significant cardiovascular or metabolic disease.&#xD;
&#xD;
          -  Participants taking prescription medicines for significant cardiovascular or metabolic&#xD;
             disease.&#xD;
&#xD;
          -  Female subjects if they are pregnant or breastfeeding at the time of recruitment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjay K Prasad</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel J Hammersley, MBBS</last_name>
    <phone>020 7352 8121</phone>
    <phone_ext>88814</phone_ext>
    <email>d.hammersley@nhs.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Imperial College</name>
      <address>
        <city>London</city>
        <zip>SW3 6LY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel J Hammersley, MBBS</last_name>
      <phone>020 7352 8121</phone>
      <phone_ext>88814</phone_ext>
      <email>d.hammersley@nhs.net</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 22, 2021</study_first_submitted>
  <study_first_submitted_qc>June 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2021</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dilated cardiomyopathy</keyword>
  <keyword>Left ventricular reverse remodelling</keyword>
  <keyword>Heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

